美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ASTRAZENECA PLC ADRhedged

53.28

0.0000

成交量：- -

成交額：- -

市值：159.83萬

市盈率：- -

高：53.28

開：53.28

低：53.28

收：53.28

52周最高：56.90

52周最低：44.36

股本：3.00萬

流通股本：1.00萬

量比：2.68

換手率：- -

股息：0.58

股息率：1.08%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

阿斯利康漲幅擴大，觸及盤中高點，最新漲幅為6%。

阿斯利康(AZN)股票7月2日盤中上漲3.92%：真相來了

TradingKey中文

多股突發利好公告，石藥聯手阿斯利康、神州數碼中標移動服務器大單

阿斯利康與石藥合作開發新型小核酸藥物

石藥創新(300765.SZ)子公司巨石生物與阿斯利康達成新型肝外遞送小干擾核酸創新藥物戰略合作

石藥集團稱與阿斯利康就開發SIRNA藥物訂立合作、選擇權及授權協議。

創新藥企攜手阿斯利康再達重磅國際合作！全市場僅有的恒生創新藥ETF華泰柏瑞連續9個交易日成交額突破10億

港股異動 | 和譽-B(02256)升逾5% 附屬與阿斯利康共同推進一項新型靶免聯合療法治療NSCLC臨床研究

和譽在港交所公告，公司之附屬公司和譽醫藥宣佈，與阿斯利康簽署戰略合作協議，共同推進一項新型靶免聯合療法治療非小細胞肺癌的

和譽-B(02256)附屬與阿斯利康達成戰略合作開展同類首創口服PD-L1抑制劑ABSK043聯合泰瑞沙®治療非小細胞肺癌的臨床研究

阿斯利康(AZN)股票7月1日盤中下跌3.02%：釋放什麼信號？

TradingKey中文

攜手共建產業創新生態 ——訪阿斯利康中國總經理林驍

阿斯利康(AZN)與第一三共重磅新藥獲歐盟CHMP推薦批准擬用於三陰性乳腺癌成年患者治療

輝瑞等製藥巨頭複製「英國劇本」：以撤資施壓德國，倒逼歐洲放寬藥價管控

數據簡報-全球製藥企業斥資數十億美元以擴大在美國的市場份額

重返腫瘤核心戰場葛蘭素史克(GSK.US)能否借Nuvalent縮小與阿斯利康差距？

智通财经网

阿斯利康加入減肥藥賽道：口服藥減重11.8%

华尔街见闻

阿斯利康GLP-1口服藥在糖尿病與肥胖症試驗中通過早期考驗

數據簡報-邦迪布吉奧埃博拉：疫苗與療法研發一覽

阿斯利康(AZN)股票6月1日收盤下跌3.17%：關鍵驅動因素揭曉

TradingKey中文

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/AZNH/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1789156800000,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"停牌","change":0,"latestTime":"09-11 16:00:00 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":2.6812474453400963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.6812474453400963,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648686711","title":"阿斯利康漲幅擴大，觸及盤中高點，最新漲幅為6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648686711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648686711?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 23:04","pubTimestamp":1783004682,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0310800379.SGD","LU2237443978.SGD","LU0289739699.SGD","LU2089984988.USD","IE00B3T34201.USD","LU2417539215.USD","LU2237443382.USD","LU2462157665.USD","LU2236285917.USD","LU2237443622.USD","LU2237443549.SGD","LU2237443895.HKD","LU0109394709.USD","LU0320765992.SGD","AZN","LU0889565916.HKD","BK4588","LU0128525929.USD","LU2468319806.SGD","LU0058720904.USD","LU0432979614.USD","LU1829250122.USD","AZNH","BK4585","LU0708994859.HKD","LU0029864427.USD","LU2456880835.USD","BK4568","BK4007","LU2237443465.HKD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685077","title":"阿斯利康(AZN)股票7月2日盤中上漲3.92%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685077","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648685077?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 22:16","pubTimestamp":1783001771,"startTime":"0","endTime":"0","summary":"• 阿斯利康与石药集团达成合作，交易总额高达17.7亿美元。\n• 肿瘤领域的新合作以及欧盟的监管进展巩固了该公司的研发管线并提振了股价。\n• 在美国劳动力市场数据降温的背景下，该股从近期临床试验失败的阴霾中反弹。","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20251024/AstraZeneca-000ba9f6d3d446b080935cd9fe1dade4.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/AstraZeneca-000ba9f6d3d446b080935cd9fe1dade4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262007437-market-movers-azn-20260702","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","LU2089984988.USD","LU0708994859.HKD","BK4007","LU0058720904.USD","LU2456880835.USD","LU2417539215.USD","LU2468319806.SGD","LU0289739699.SGD","LU0029864427.USD","LU2237443978.SGD","LU0310800379.SGD","AZNH","LU1829250122.USD","LU2237443622.USD","BK4585","BK4588","LU2237443895.HKD","LU1267930573.SGD","LU0128525929.USD","LU2462157665.USD","LU0320765992.SGD","AZN","LU0109394709.USD","LU0432979614.USD","IE00B3T34201.USD","LU2237443382.USD","LU2237443465.HKD","LU2237443549.SGD","LU0889565916.HKD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648688848","title":"多股突發利好公告，石藥聯手阿斯利康、神州數碼中標移動服務器大單","url":"https://stock-news.laohu8.com/highlight/detail?id=2648688848","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648688848?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 20:51","pubTimestamp":1782996660,"startTime":"0","endTime":"0","summary":"合同中标与战略合作方面，石药创新控股子公司将携手阿斯利康，围绕新型小干扰核酸候选药物达成深度战略合作，旗下 SYS6043同步纳入突破性治疗品种名单；东安动力二季度斩获8家企业共计12项定点协议，拓展下游市场；云南能投拿下华宁县大龙山风电场（二期）开发权；神州数码控股子公司成功中标中国移动 PC 服务器集中采购项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmmmu2690850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0289739699.SGD","LU0310800379.SGD","LU0072913022.USD","LU1152091168.USD","IE00B031HY20.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU2237443978.SGD","LU0889565916.HKD","LU2468319806.SGD","LU0029864427.USD","LU1960683339.HKD","IE00BZ08YT58.USD","LU1829250122.USD","LU1993786604.SGD","LU0432979614.USD","LU2237443382.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU2039709279.SGD","LU2237443549.SGD","LU0880133367.SGD","LU2237443622.USD","01093","LU1328277881.USD","SG9999004220.SGD","LU0315179316.USD","LU2236285917.USD","LU0708994859.HKD","BK1191","BK1515","BK0250","LU1226288253.USD","LU2237443895.HKD","AZN","000034","LU0109394709.USD","LU1226288170.HKD","LU2089984988.USD","BK4588","LU1008478684.HKD","LU0326950275.SGD","IE00B3T34201.USD","LU0320765992.SGD","AZNH","LU2456880835.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU0058720904.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648506369","title":"阿斯利康與石藥合作開發新型小核酸藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2648506369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648506369?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 17:49","pubTimestamp":1782985786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443382.USD","LU2237443895.HKD","LU2456880835.USD","BK4588","BK4568","LU2089984988.USD","LU2462157665.USD","LU0058720904.USD","AZN","LU2237443465.HKD","LU0708994859.HKD","BK4007","LU2468319806.SGD","LU0289739699.SGD","LU0128525929.USD","LU0889565916.HKD","LU2236285917.USD","IE00B3T34201.USD","LU2237443549.SGD","LU0432979614.USD","LU1829250122.USD","AZNH","BK4585","LU2237443622.USD","LU0109394709.USD","LU0320765992.SGD","LU1267930573.SGD","LU0310800379.SGD","LU2417539215.USD","LU0029864427.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648503310","title":"石藥創新(300765.SZ)子公司巨石生物與阿斯利康達成新型肝外遞送小干擾核酸創新藥物戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648503310","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648503310?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 16:53","pubTimestamp":1782982410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司与阿斯利康于2026年7月1日签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。阿斯利康将向巨石生物支付首付款3,000万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443895.HKD","LU0320765992.SGD","LU0708994859.HKD","LU2237443622.USD","LU0310800379.SGD","BK0226","LU0109394709.USD","159992","LU0058720904.USD","LU0889565916.HKD","LU0029864427.USD","BK1161","LU2089984988.USD","LU0289739699.SGD","BK4585","LU1267930573.SGD","LU2236285917.USD","BK4568","LU2417539215.USD","LU2237443465.HKD","06978","300765","LU0128525929.USD","AZNH","LU1829250122.USD","LU2237443978.SGD","LU2456880835.USD","BK1574","BK4007","LU2468319806.SGD","BK4588","LU2462157665.USD","LU0432979614.USD","LU2237443382.USD","LU2237443549.SGD","AZN","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648508319","title":"石藥集團稱與阿斯利康就開發SIRNA藥物訂立合作、 選擇權及授權協議。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648508319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648508319?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 16:32","pubTimestamp":1782981130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","LU1829250122.USD","LU2456880835.USD","LU0432979614.USD","LU2237443895.HKD","LU0310800379.SGD","LU1267930573.SGD","LU0320765992.SGD","LU2236285917.USD","BK4568","LU0058720904.USD","LU2237443382.USD","LU2237443549.SGD","LU0109394709.USD","AZN","LU0708994859.HKD","LU2089984988.USD","LU2417539215.USD","LU2468319806.SGD","LU0029864427.USD","IE00B3T34201.USD","LU2237443978.SGD","BK4585","LU2237443465.HKD","AZNH","LU2237443622.USD","BK4588","LU0289739699.SGD","BK4007","LU2462157665.USD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648579477","title":"創新藥企攜手阿斯利康再達重磅國際合作！全市場僅有的恒生創新藥ETF華泰柏瑞連續9個交易日成交額突破10億","url":"https://stock-news.laohu8.com/highlight/detail?id=2648579477","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648579477?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 13:17","pubTimestamp":1782969420,"startTime":"0","endTime":"0","summary":"某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64亿元，创下今年4月3日之后阶段新高，最新规模24.48亿元，场内流动性表现较亮眼。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0289739699.SGD","LU2456880835.USD","LU2237443549.SGD","LU1829250122.USD","06978","LU0029864427.USD","LU0128525929.USD","AZN","LU2468319806.SGD","159992","LU2237443895.HKD","LU2237443465.HKD","LU2089984988.USD","BK1574","LU1267930573.SGD","LU0320765992.SGD","LU2237443382.USD","LU2236285917.USD","LU0889565916.HKD","LU2462157665.USD","LU0109394709.USD","LU0708994859.HKD","LU2237443978.SGD","LU2237443622.USD","520500","AZNH","BK4007","LU0310800379.SGD","LU0432979614.USD","BK4585","BK4568","BK1161","LU2417539215.USD","LU0058720904.USD","IE00B3T34201.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648357688","title":"港股異動 | 和譽-B(02256)升逾5% 附屬與阿斯利康共同推進一項新型靶免聯合療法治療NSCLC臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648357688","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648357688?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 11:32","pubTimestamp":1782963123,"startTime":"0","endTime":"0","summary":"消息面上，7月2日，和誉-B发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该研究的新药临床试验申请已于2026年5月20日获得国家药品监督管理局批准，本项II期研究由和誉医药主导，和誉医药和阿斯利康将共同承担该临床试验的相关职责。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3T34201.USD","LU1267930573.SGD","LU2476274720.SGD","LU2237443382.USD","LU2236285917.USD","IE00B543WZ88.USD","LU2237443622.USD","AZNH","BK4588","02256","LU2089984988.USD","LU2456880835.USD","IE00BPRC5H50.USD","LU0320765992.SGD","LU2476274308.USD","LU2462157665.USD","LU2237443895.HKD","BK4568","LU0109394709.USD","LU0128525929.USD","LU0029864427.USD","LU2468319806.SGD","IE00B5MMRT66.SGD","VXUS","LU0889565916.HKD","LU2778985437.USD","LU2417539215.USD","LU0310800379.SGD","BK4585","LU0058720904.USD","LU1829250122.USD","LU2237443465.HKD","LU2237443549.SGD","LU2237443978.SGD","BK4007","LU0289739699.SGD","LU0432979614.USD","BK1161","AZN","LU2488822045.USD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648152730","title":"和譽在港交所公告，公司之附屬公司和譽醫藥宣佈，與阿斯利康簽署戰略合作協議，共同推進一項新型靶免聯合療法治療非小細胞肺癌的","url":"https://stock-news.laohu8.com/highlight/detail?id=2648152730","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648152730?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 08:16","pubTimestamp":1782951413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443895.HKD","LU0320765992.SGD","LU0708994859.HKD","LU2237443622.USD","LU0310800379.SGD","LU0109394709.USD","LU0058720904.USD","LU0889565916.HKD","LU0029864427.USD","LU2089984988.USD","LU0289739699.SGD","BK4585","LU1267930573.SGD","LU2236285917.USD","BK4568","LU2417539215.USD","LU2237443465.HKD","LU0128525929.USD","AZNH","LU1829250122.USD","LU2237443978.SGD","LU2456880835.USD","BK4007","LU2468319806.SGD","BK4588","LU2462157665.USD","LU0432979614.USD","LU2237443382.USD","LU2237443549.SGD","AZN","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和譽-B(02256)附屬與阿斯利康達成戰略合作開展同類首創口服PD-L1抑制劑ABSK043聯合泰瑞沙®治療非小細胞肺癌的臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648220025?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2236285917.USD","LU1169589451.USD","LU2089984988.USD","LU2476274308.USD","LU0708994859.HKD","LU0889565916.HKD","BK4007","LU2488822045.USD","LU0058720904.USD","LU2456880835.USD","LU2417539215.USD","IE00B543WZ88.USD","LU2468319806.SGD","LU0289739699.SGD","LU2778985437.USD","LU0029864427.USD","LU2237443978.SGD","LU1169590202.USD","LU0310800379.SGD","AZNH","LU1829250122.USD","LU2237443622.USD","02256","BK4585","BK4588","BK4023","LU2237443895.HKD","LU1267930573.SGD","PD","LU2462157665.USD","BK1161","LU0320765992.SGD","IE00B5MMRT66.SGD","AZN","LU0109394709.USD","LU2476274720.SGD","LU0432979614.USD","IE00B3T34201.USD","IE00BPRC5H50.USD","LU2237443382.USD","LU2237443465.HKD","LU2237443549.SGD","LU0128525929.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648540101","title":"阿斯利康(AZN)股票7月1日盤中下跌3.02%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2648540101","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648540101?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 01:15","pubTimestamp":1782926138,"startTime":"0","endTime":"0","summary":"• 实验性疗法的临床试验失败和监管延迟给AstraZeneca的股价带来了压力。\n• 市场广泛轮动至周期性板块，正导致资金从防御性医药股中流出。\n• 用于药物研发的新兴人工智能（AI）平台正在促使投资者重新评估传统制药企业的估值。","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20251024/AstraZeneca-000ba9f6d3d446b080935cd9fe1dade4.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/AstraZeneca-000ba9f6d3d446b080935cd9fe1dade4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262004779-market-movers-azn-20260701","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2462157665.USD","LU2089984988.USD","LU1267930573.SGD","LU0058720904.USD","LU2237443978.SGD","LU0320765992.SGD","LU2456880835.USD","LU0109394709.USD","BK4007","LU0128525929.USD","LU2417539215.USD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443549.SGD","LU2236285917.USD","LU0708994859.HKD","BK4588","AZN","LU0310800379.SGD","LU2468319806.SGD","BK4585","LU2237443382.USD","LU2237443895.HKD","IE00B3T34201.USD","AZNH","LU2237443622.USD","LU2237443465.HKD","BK4568","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647003353","title":"攜手共建產業創新生態 ——訪阿斯利康中國總經理林驍","url":"https://stock-news.laohu8.com/highlight/detail?id=2647003353","media":"经济日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647003353?lang=zh_tw&edition=fundamental","pubTime":"2026-06-30 06:05","pubTimestamp":1782770747,"startTime":"0","endTime":"0","summary":"“中国‘十五五’规划释放了清晰信号，将坚定推进高水平对外开放，中国生物医药产业将迎来全新发展机遇，为跨国药企深耕中国市场筑牢坚实基础。”阿斯利康中国总经理林骁近期在第七届跨国公司领导人青岛峰会期间接受经济日报记者采访时说。今年1月，阿斯利康宣布到2030年在华投资超1000亿元人民币，全面深化在研发、生产、商业化、生态合作的全价值链布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303787106392.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303787106392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2237443622.USD","LU0310800379.SGD","LU0708994859.HKD","BK4585","LU2456880835.USD","LU2462157665.USD","LU2237443895.HKD","LU2236285917.USD","LU2417539215.USD","IE00B3T34201.USD","LU0320765992.SGD","BK4007","LU0432979614.USD","LU0889565916.HKD","BK4568","LU1829250122.USD","BK4588","LU2237443549.SGD","LU0029864427.USD","LU2237443978.SGD","LU0109394709.USD","LU2237443382.USD","LU2237443465.HKD","AZNH","LU1267930573.SGD","LU0058720904.USD","LU0289739699.SGD","AZN","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354848","title":"阿斯利康(AZN)與第一三共重磅新藥獲歐盟CHMP推薦批准 擬用於三陰性乳腺癌成年患者治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354848","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646354848?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 19:17","pubTimestamp":1782472640,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药巨头阿斯利康 与日本第一三共联合开发的新一代抗癌药物 Datroway获欧洲药品管理局下属的人用药品委员会推荐批准作为单药一线疗法，用于治疗不适合接受 PD-1/PD-L1 抑制剂的不可切除或转移性三阴性乳腺癌成年患者。CHMP 的积极推荐主要基于 TROPION-Breast02 第三期全球临床试验的压倒性数据。业内分析认为，该管线的顺利推进将进一步夯实阿斯利康与第一三共在全球 ADC 药物赛道的霸主地位，并为两家公司未来的营收增长注入强劲的确定性。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301958","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","LU0432979614.USD","FESXmain","LU2237443549.SGD","AZNH","BK4585","CHMP","LU0058720904.USD","LU0128525929.USD","LU2237443382.USD","LU2456880835.USD","LU2237443978.SGD","LU2462157665.USD","LU0889565916.HKD","BK4568","BK4588","LU2237443622.USD","LU2417539215.USD","LU2237443895.HKD","LU0029864427.USD","FSXEmain","AZN","LU0109394709.USD","LU1267930573.SGD","LU1829250122.USD","LU0310800379.SGD","BK4007","LU0708994859.HKD","LU2236285917.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B3T34201.USD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644435217","title":"輝瑞等製藥巨頭複製「英國劇本」：以撤資施壓德國，倒逼歐洲放寬藥價管控","url":"https://stock-news.laohu8.com/highlight/detail?id=2644435217","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644435217?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 20:32","pubTimestamp":1781699555,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，面对欧洲各国首都对药品定价的抵制，全球制药公司正在搬出近期在英国取得成功的“老剧本”：以撤回投资和扩张计划为威胁，向政策制定者施压。最新的目标是德国，该国目前正在辩论一项旨在收紧药品支出的立法。辉瑞上周致信德国总理，警告称由于该国目前的药品定价政策，其在德国的投资正面临风险；而阿斯利康则警告称，如果这些变革付诸实施，它可能不会在德国推出新药。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455695.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999011175.SGD","LU0323591593.USD","LU0320765992.SGD","LU1720051108.HKD","IE00BJT1NW94.SGD","LU1894683264.USD","LU2491050071.SGD","SG9999015952.SGD","LU0109394709.USD","IE00BLSP4452.SGD","LU1712237335.SGD","LU0122379950.USD","LU0820561818.USD","BK4585","SG9999003800.SGD","IE0004445239.USD","LU1267930573.SGD","LU2361044949.HKD","LU2236285917.USD","LU2491050154.USD","SG9999018865.SGD","SG9999002232.USD","LU2750360997.AUD","IE00BJJMRX11.SGD","LU2168564495.EUR","LU2491049909.HKD","LU1883839398.USD","LU1868836591.USD","SGXZ31699556.SGD","SG9999015945.SGD","LU2237443465.HKD","LU2471134523.USD","SG9999013999.USD","LU2471134796.USD","LU0158827948.USD","LU2168564065.EUR","SG9999017495.SGD","IE0005OL40V9.USD","SGXZ57979304.SGD","LU0133085943.USD","LU0096364046.USD","LU0943347566.SGD","LU2471134879.HKD","AZNH","LU2213496289.HKD","LU0820561909.HKD","LU1829250122.USD","IE00BN29S564.USD","LU0354030511.USD","LU2168564222.USD","LU2361045086.USD","LU2456880835.USD","IE00B1BXHZ80.USD","BK4516","LU2211815571.USD","IE00B2B36J28.USD","IE00B775H168.HKD","LU0306806265.USD","LU0106261372.USD","LU2265009873.SGD","LU1548497426.USD","BK4599","LU2023251221.USD","LU2108987350.USD","LU2089283258.USD","LU0320765059.SGD","LU1323610961.USD","IE00B3T34201.USD","LU1023059063.AUD","LU0306807586.USD","LU0061475181.USD","LLII","LU0708994859.HKD","LU2063271972.USD","LU1064131342.USD","LU2471134952.CNY","LU1720051017.SGD","LU0079474960.USD","IE00B4JS1V06.HKD","LU0289739699.SGD","LU2552382132.HKD","IE0004445015.USD","LU0109391861.USD","LU0225283273.USD","LU2089284900.SGD","LU1868837136.USD","LU0471298694.HKD","BK4568","LU1551013425.SGD","LU0640476718.USD","LU2237438978.USD","LU1868836757.USD","LU2461242641.AUD","LU0683600562.USD","LU1232071149.USD","LU2417539215.USD","IE00B19Z3B42.SGD","LU0266013472.USD","LU2602419157.SGD","LU1093756325.SGD","GB00BDT5M118.USD","SG9999014906.USD","LU0985481810.HKD","IE0001KFT4U8.USD","LU0203201768.USD","IE00BFSS8Q28.SGD","LU1868837300.USD","LU0456855351.SGD","LU0786609619.USD","LU0094547139.USD","LU0234572021.USD","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0820562030.AUD","LU1974910355.USD","SGXZ51526630.SGD","LU2596442595.SGD","LU0238689110.USD","LU2462157665.USD","SG9999001176.USD","IE00BJLML261.HKD","LU0432979614.USD","LU2087625088.SGD","LU1988902786.USD","LU2237443382.USD","LU2264538146.SGD","SG9999014914.USD","LU2237443549.SGD","AZN","IE0002141913.USD","LLYX","LU1629891620.HKD","IE00BBT3K403.USD","IE00BK4W5L77.USD","IE00BFTCPJ56.SGD","BK4534","LU1127390331.HKD","LU0672654240.SGD","LU2237443622.USD","LU2746668461.USD","LU0321505868.SGD","LU2106854487.HKD","LU0058720904.USD","LU0889565916.HKD","LU2089984988.USD","LU0964807845.USD","LU1989771016.USD","LU1983299246.USD","IE00BK4W5M84.HKD","LU1057294990.SGD","LU0385154629.USD","LU1061106388.HKD","LU1551013342.USD","ELIS","IE00BFSS7M15.SGD","PFE","LU1804176565.USD","LU0256863902.USD","LU0787776722.HKD","LU1814569148.SGD","LU2023250504.SGD","BK4592","LU1093756168.USD","LU0203202063.USD","IE00B4R5TH58.HKD","LU1894683348.USD","LU0114720955.EUR","LU2112291526.USD","LU0225771236.USD","LU2552382058.USD","LU0354030438.USD","IE00BLSP4239.USD","LU2357305700.SGD","LU2237443978.SGD","LU2896262040.SGD","LU1623119135.USD","IE00BJJMRY28.SGD","LU0006306889.USD","LLYZ","LU0158827781.USD","LU0321505439.SGD","LU2746668974.SGD","SG9999018857.SGD","SGXZ99366536.SGD","BK4533","LU2168564149.EUR","SG9999001176.SGD","LU1291159041.SGD","IE00BKDWB100.SGD","LU1366192091.USD","LU0353189763.USD","IE0002270589.USD","LU0823434583.USD","IE00B7KXQ091.USD","SG9999002224.SGD","IE00BKPKM429.USD","IE000M9KFDE8.USD","SG9999015986.USD","LU2237443895.HKD","LU0256863811.USD","LU1145028129.USD","LU1868836914.USD","LU1035775433.USD","LU0170899867.USD","LU0310800379.SGD","LU1267930730.SGD","LU1280957306.USD","SGXZ81514606.USD","IE00B1XK9C88.USD","SG9999015978.USD","LU0029864427.USD","LU0198837287.USD","LU0689472784.USD","SG9999014898.SGD","BK4581","IE0009355771.USD","LU2756315664.SGD","SG9999014880.SGD","IE00B19Z3581.USD","LU0316494557.USD","LU0097036916.USD","LU0471298777.SGD","LU0823434740.USD","LU2023250330.USD","LU2028103732.USD","LU0225284248.USD","LLY","LU2168563687.JPY","LU2360106947.USD","LU0823416689.USD","LU2750360641.GBP","LU1066053197.SGD","LU0708995401.HKD","LU2361044865.SGD","LU2324357040.USD","LU0210536198.USD","LU2271345857.HKD","LU0128525929.USD","LU0466842654.USD","LU0882574055.USD","LU2756315318.SGD","BK4007","IE00BWXC8680.SGD","LU1069344957.HKD","LU0868494617.USD","LU1066051498.USD","BK4588","LU0353189680.USD","LU0882574139.USD","LU1917777945.USD","LU2552382215.SGD","ELIL","BK4550","LU2111349929.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520595","title":"數據簡報-全球製藥企業斥資數十億美元以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520595","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520595?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:41","pubTimestamp":1781527269,"startTime":"0","endTime":"0","summary":"路透6月15日 - 全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔市投资约10亿美元，以加强其眼科护理业务在美国本土的制造能力。默克动物保健部门将投资8.95亿美元，用于扩建其位于堪萨斯州的制造和研发基地，这是该公司截至2028年总额达90亿美元的美国投资计划的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4T42N15M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","BK4516","LU1291159041.SGD","SGXZ31699556.SGD","LU2108987350.USD","LU1983299246.USD","LU2471134796.USD","BK4592","LU0965509010.AUD","LU1629891620.HKD","LU1162221912.USD","LU0708995401.HKD","LU0965509283.SGD","SG9999014567.USD","LU1232071149.USD","LU2433249047.HKD","LU0942090050.USD","LU2552382058.USD","LU2129689431.USD","LU2236285917.USD","LU0640476718.USD","IE00B775H168.HKD","AZN","GSK","IE000M9KFDE8.USD","LU0225283273.USD","SG9999003800.SGD","IE00B7SZLL34.SGD","LU1066051225.USD","LU1929549753.HKD","LU2023250330.USD","LU1057294990.SGD","BK4533","IE00B3PB1722.GBP","LU1720051017.SGD","LU0795875169.SGD","IE000MB6IJN5.SGD","LU1548497426.USD","04332","LU0306806265.USD","LU1935042991.SGD","LU2089283258.USD","LU1804176565.USD","LU1814569148.SGD","LU2125909593.SGD","LU0823434740.USD","BK4139","BK4550","LU2111349929.HKD","LU0208291251.USD","LU1043141396.HKD","LU2211815571.USD","LU2129689605.HKD","LU1093756325.SGD","LU2133065610.SGD","LU0345770993.USD","LU0130517989.USD","BK4504","BK4583","BK4578","LU2417539215.USD","LU0266013472.USD","LU0323591593.USD","LU1116320901.HKD","IE00BZ1G4Q59.USD","LU0889565916.HKD","LU2491050071.SGD","LU0511384066.AUD","LU2063271972.USD","LU0354030438.USD","LU0868494708.USD","LU2592432038.USD","LU1585245621.USD","LU2403377893.USD","AMGN","LU1228905540.USD","LU1989772923.USD","LU1069344957.HKD","LU1221951129.SGD","LU0320765646.SGD","LLYX","LU0234572021.USD","MRK","BK4585","LU0225284248.USD","LU1228905037.USD","LU0320765059.SGD","LU0211327993.USD","LU1116320737.USD","LU1699723380.USD","LU1868836757.USD","LU1267930573.SGD","LU1571399168.USD","IE0009355771.USD","IE00B19Z9Z06.USD","LU0097036916.USD","IE00BK4W5L77.USD","LU2264538146.SGD","LU0738911758.USD","LU1923622614.USD","IE000WAW04H5.SGD","LU1894683348.USD","SG9999014914.USD","LU1066051811.HKD","LU1670628061.USD","BK4588","LU0289739699.SGD","LU1280957306.USD","LU2237443978.SGD","GSK.UK","IE00BVYPNW00.USD","IE00B42XCP33.USD","LU1037948897.HKD","GSKH","IE0034235303.USD","LU2360106947.USD","LU0882574139.USD","LU2112291526.USD","IE00BN8TJ469.HKD","IE0004445015.USD","IE00BKVL7J92.USD","SG9999001440.SGD","IE00BN29S564.USD","LU2471134523.USD","LU0069063385.USD","LU1732799900.SGD","LU1267930730.SGD","LU1066051498.USD","GB00BDT5M118.USD","JNJ","LU1674673428.USD","LU2468319806.SGD","LU2213496289.HKD","LU0965509101.SGD","ELIL","SG9999015341.SGD","LLY","LU2756315318.SGD","LU1674673691.USD","LU0426417589.USD","LU0006306889.USD","LU0170899867.USD","LU0345770308.USD","LU0353189680.USD","LU0868494617.USD","IE00BKPKM429.USD","IE000SO60NU8.SGD","LU1244550577.SGD","LU2237443382.USD","IE00BJJMRZ35.SGD","LU0106261372.USD","LU1496350171.SGD","LU0471298694.HKD","LU0889566641.SGD","IE00BJJMRX11.SGD","LU2491049909.HKD","LU2168564222.USD","LLII","LU1430594728.SGD","CSL.AU","LU0225771236.USD","LU0545039389.USD","LU0306807586.USD","LU2271345857.HKD","LU2430703095.HKD","BK7508","LU1032955483.USD","LU2237443549.SGD","LU0689626769.HKD","LU1941712348.USD","LU0057025933.USD","BK4534","IE00BLSP4452.SGD","LU0109394709.USD","LU0345769631.USD","SG9999017495.SGD","LU0672654240.SGD","LU0792757196.USD","LU0471298777.SGD","BK4566","LU0661504455.SGD","LU1121112475.USD","LU2505996509.AUD","IE0002141913.USD","BK4599","IE000F7OJYX1.SGD","LU1066053197.SGD","LU2023250843.SGD","LU0477156953.USD","LU1221951046.USD","LU0683600562.USD","LU0070302665.USD","LU2552382215.SGD","LU1670627923.USD","SG9999014559.SGD","LU1934455277.USD","LU0289961442.SGD","LU0158827948.USD","LU0965508806.USD","LU2087621335.USD","LU2129689514.USD","LU0061475181.USD","LU0385154629.USD","LU1551013425.SGD","LU1917777945.USD","LU0029864427.USD","AZNH","LU1043141123.HKD","LU0133085943.USD","LU1003077747.HKD","LU1712237335.SGD","LU2125154778.USD","SG9999002232.USD","LU2602419157.SGD","LU0109391861.USD","LU2756315664.SGD","LU2237438978.USD","LU0426412945.USD","SG9999015945.SGD","LU0353189763.USD","IE0005OL40V9.USD","SG9999014898.SGD","LU0456855351.SGD","LU2324357040.USD","BIIB","LU2360032135.SGD","SG9999015978.USD","BK7511","LU1366192091.USD","LU0114720955.EUR","LU0994945656.USD","IE00BK4W5M84.HKD","LU2361044865.SGD","LU2471134879.HKD","IE0002270589.USD","LU1061106388.HKD","BK4532","BK7501","LU0211328371.USD","SG9999014906.USD","LU0079474960.USD","LU0158827781.USD","LU0128525929.USD","IE00B7KXQ091.USD","LU1718418525.SGD","SG9999018857.SGD","IE000BZT7R73.USD","LU0310800379.SGD","IE00BJT1NW94.SGD","IE00BFSS7M15.SGD","LU2430703251.USD","SG9999015986.USD","LU0432979614.USD","LU0210536198.USD","LU2462157665.USD","LU1023059063.AUD","LU0417517546.SGD","LU1032466523.USD","LU0203345920.USD","IE00B894F039.SGD","LU0316494557.USD","LU1868836591.USD","LU1093756168.USD","IE00BSNM7G36.USD","LU1839511570.USD","LU1201861249.SGD","LU1069347547.HKD","IE00B19Z9P08.USD","LU2125909247.SGD","IE00BLSP4239.USD","LU2242646821.SGD","SG9999015952.SGD","LU0912757837.SGD","SG9999011175.SGD","IE00BJLML261.HKD","LU0310799852.SGD","LU2491050154.USD","LU1035773651.USD","LU1883839398.USD","LU1145028129.USD","SG9999014542.SGD","IE00BDGV0183.EUR","IE0001KFT4U8.USD","LU0321505868.SGD","LU0211331839.USD","SGXZ81514606.USD","LU0256863902.USD","LU0786609619.USD","LU2746668461.USD","IE00B2B36J28.USD","LU0289739343.SGD","LU0787776722.HKD","LU1732800096.USD","LU1989771016.USD","SG9999002224.SGD","BK4581","IE00BGHQF631.EUR","IE00BVYPNV92.GBP","LU1720051108.HKD","LU2237443622.USD","LU2265009873.SGD","LU1974910355.USD","IE0004445239.USD","LU2456880835.USD","SG9999001176.USD","LU2168564149.EUR","SG9999014575.USD","LU1074936037.SGD","SGXZ57979304.SGD","LU1989772840.SGD","LU1037948541.HKD","LU0203347892.USD","LU2596442595.SGD","BK7067","LU1059921491.USD","LU1868837136.USD","IE00B1BXHZ80.USD","LU2237443895.HKD","LU0820562030.AUD","LU0345769128.USD","LU0820561909.HKD","LU0689472784.USD","LU1894683264.USD","LU0980610538.SGD","LU2168564495.EUR","LU1934455194.USD","LU0320765992.SGD","LU1267930490.SGD","IE00BJJMRY28.SGD","LU2028103732.USD","LU0943347566.SGD","IE00BFTCPJ56.SGD","LU0265550359.USD","LU0210528500.USD","LU0466842654.USD","LU2487616109.SGD","LU0553294199.USD","LU2750360997.AUD","LU0472753341.HKD","LU2896262040.SGD","IE00B19Z3B42.SGD","LU1496350502.SGD","IE00BFXG1179.USD","LU0321505439.SGD","LU1261432733.SGD","LU2461242641.AUD","LU0648001328.SGD","LU2357627491.SGD","LU2242652126.USD","LU2125154935.USD","LU1868837300.USD","LU2089984988.USD","BK4007","LU1623119135.USD","LU0949170772.SGD","ABBV","LU0198837287.USD","LU0265550946.USD","IE00B3T34201.USD","LU0203202063.USD","LU1267930813.SGD","LU0985320562.USD","LU2552382132.HKD","LU0985481810.HKD","LU0320765489.SGD","LU0823416689.USD","SGXZ51526630.SGD","LU0708994859.HKD","LU1988902786.USD","LU2106854487.HKD","LU2023250504.SGD","LU0545562505.USD","LU2750360641.GBP","LU2357305700.SGD","LU0823434583.USD","LU1868836914.USD","LU1035775433.USD","LU0058720904.USD","LU2505996681.GBP","PFE","IE00B4R5TH58.HKD","LU0234570918.USD","LU1064131342.USD","LU0096364046.USD","LU0053666078.USD","LU0122379950.USD","LU0354030511.USD","LU1196500208.SGD","LU0964807845.USD","LU1941712264.USD","LU2471134952.CNY","LU2746668974.SGD","LU1778281490.HKD","LU0238689110.USD","LU1244550221.USD","LU0070217475.USD","LU1506573853.SGD","LU1914381329.SGD","LU1829250122.USD","IE00BWXC8680.SGD","LU2361044949.HKD","LU0130102774.USD","LU0203201768.USD","SG9999014880.SGD","LU2361045086.USD","LU1551013342.USD","IE0000B7K699.USD","LU2347655156.SGD","IE00BKDWB100.SGD","SG9999001176.SGD","IE00B4JS1V06.HKD","LU1323610961.USD","LU2087625088.SGD","LU2168564065.EUR","ELIS","SGXZ99366536.SGD","LU2168563687.JPY","LU0256863811.USD","LU2023251221.USD","LU1127390331.HKD","LU0861579265.USD","LU0124676726.USD","LU0795875086.SGD","IE00BBT3K403.USD","LU2089284900.SGD","SG9999015358.SGD","IE00B19Z3581.USD","GILD","IE00B1XK9C88.USD","LU0094547139.USD","BK4568","IE00BFSS8Q28.SGD","LU2430703178.SGD","BK4559","SG9999018865.SGD","LU0882574055.USD","LU0820561818.USD","LU2237443465.HKD","LU1244550494.USD","LLYZ","LU1934455863.HKD","SG9999013999.USD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642189402","title":"重返腫瘤核心戰場 葛蘭素史克(GSK.US)能否借Nuvalent縮小與阿斯利康差距？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642189402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642189402?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 15:56","pubTimestamp":1781164594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克以创纪录的106亿美元收购美国生物技术公司Nuvalent，此举将加快这家英国制药巨头旗下抗癌药物业务的重建步伐，以应对来自更大竞争对手阿斯利康和罗氏的竞争压力。米尔斯在周二宣布收购Nuvalent后对记者表示。葛兰素史克并不打算在全部肿瘤领域与默沙东、阿斯利康或罗氏正面竞争，但将其视为潜在的增长领域。收购Nuvalent将为葛兰素史克产品组合增添两款晚期药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["GSKH","LU2237443978.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU2417539215.USD","LU2237443382.USD","LU2462157665.USD","LU2236285917.USD","LU2237443622.USD","LU2237443549.SGD","LU2237443895.HKD","LU0109394709.USD","LU0320765992.SGD","AZN","BK4532","LU0889565916.HKD","NUVL","BK4588","LU0058720904.USD","BK4539","BK4139","LU1829250122.USD","AZNH","BK4585","GSK","LU2456880835.USD","BK4568","BK4007","GSK.UK","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642452868","title":"阿斯利康加入減肥藥賽道：口服藥減重11.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642452868","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642452868?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 14:19","pubTimestamp":1780985960,"startTime":"0","endTime":"0","summary":"阿斯利康的口服减肥药elecoglipron二期数据亮眼，36周内减重11.8%。虽效果略逊于礼来，但5%的副作用退出率远低于礼来的17%，且无需空腹。目前该药已进三期，正推进与心肾药联合开发以形成差异化竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3774191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2456880835.USD","LU2237443465.HKD","LU2237443549.SGD","LU2462157665.USD","LU0320765992.SGD","BK4588","BK4585","LU2236285917.USD","LU0289739699.SGD","LU1829250122.USD","LU0109394709.USD","BK4568","LU0889565916.HKD","LU2237443382.USD","AZNH","LU2237443895.HKD","AZN","LU0058720904.USD","IE00B3T34201.USD","LU2237443622.USD","LU2237443978.SGD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1163381786","title":"阿斯利康GLP-1口服藥在糖尿病與肥胖症試驗中通過早期考驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1163381786","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163381786?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 06:27","pubTimestamp":1780957629,"startTime":"0","endTime":"0","summary":"根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4590","AZNH","IE00B3T34201.USD","LU0109394709.USD","LU2417539215.USD","BK4007","LU0058720904.USD","BK4144","BK4588","LU0320765992.SGD","LU2462157665.USD","GLP","LU0289739699.SGD","LU1829250122.USD","LU2236285917.USD","LU2237443978.SGD","LU2237443622.USD","BK4568","LU2237443465.HKD","LU2237443895.HKD","LU2237443382.USD","AZN","LU2456880835.USD","LU2237443549.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641169538","title":"數據簡報-邦迪布吉奧埃博拉：疫苗與療法研發一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=2641169538","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641169538?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 00:29","pubTimestamp":1780590599,"startTime":"0","endTime":"0","summary":"数据简报-邦迪布吉奥埃博拉：疫苗与疗法研发一览在第42和43段中补充了关于罗氏检测的细节Mariam Sunny/Jennifer Rigby. 与更常见的扎伊尔毒株不同，目前尚无针对邦迪布吉奥毒株的获批疫苗或治疗方法。邦迪布吉奥埃博拉病毒的致死率高达40%。CEPI表示，将初步投资高达860万美元用于该疫苗的研发。该药物最初针对苏丹埃博拉病毒株进行研究，在早期试验中被证实安全且耐受性良好。据该公司称，实验室研究显示该药物对邦迪布吉奥埃博拉病毒具有活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nL4T42C1HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","AZNH","IE0002141913.USD","SG9999014567.USD","LU0114720955.EUR","LU1116320901.HKD","BK4568","LU1989772840.SGD","LU1037948897.HKD","IE00BLSP4452.SGD","LU1974910355.USD","BK4516","LU1917777945.USD","LU0106261372.USD","LU0130102774.USD","LU1941712264.USD","LU2237443895.HKD","BK4559","LU1066051811.HKD","LU1061106388.HKD","LU1989771016.USD","BK4534","LU0109394709.USD","LU1829250122.USD","LU1093756325.SGD","BK4533","LU2456880835.USD","LU2112291526.USD","SG9999015952.SGD","MRK","GILD","LU2237443549.SGD","LU1093756168.USD","LU1989772923.USD","LU2237443978.SGD","LU0006306889.USD","BK4501","BK4139","LU2361044865.SGD","LU2324357040.USD","IE00BKVL7J92.USD","LU1923622614.USD","LU0234570918.USD","LU0265550359.USD","LU0211331839.USD","LU2433249047.HKD","LU2237438978.USD","LU2361044949.HKD","LU0648001328.SGD","BK4585","LU0889565916.HKD","LU0130517989.USD","IE00BJJMRZ35.SGD","SG9999001176.SGD","SG9999013999.USD","IE0002270589.USD","LU1069347547.HKD","LU2491049909.HKD","LU2089984988.USD","LU2357627491.SGD","IE00B2B36J28.USD","LU0058720904.USD","RHHBY","LU0965509101.SGD","LU2087621335.USD","SG9999001176.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU2023250843.SGD","BK4551","LU0859254822.USD","SG9999015945.SGD","BK4583","LU0320765992.SGD","IE00BJT1NW94.SGD","LU2023250504.SGD","LU0868494708.USD","IE00BLSP4239.USD","LU0477156953.USD","LU2237443622.USD","LU0070302665.USD","BK4007","LU1291159041.SGD","LU1699723380.USD","LU1571399168.USD","MRNX","SG9999015358.SGD","LU1201861249.SGD","SG9999002224.SGD","LU1934455863.HKD","MRNY","LU2106854487.HKD","IE00B19Z3B42.SGD","LU0266013472.USD","LU0965509283.SGD","LU0868494617.USD","LU1116320737.USD","BK4532","LU1778281490.HKD","LU0823416689.USD","LU2491050071.SGD","LU2362541273.HKD","IE00BZ1G4Q59.USD","BK4588","LU1430594728.SGD","LU1934455194.USD","LU0320765646.SGD","LU2461242641.AUD","LU0098860793.USD","IE000M9KFDE8.USD","IE00BN8TJ469.HKD","SG9999015978.USD","AZN","LU1037948541.HKD","LU0861579265.USD","SGXZ57979304.SGD","LU1066051498.USD","BK4566","LU1066051225.USD","LU2125909247.SGD","LU1934455277.USD","SG9999015986.USD","BK4578","SG9999014542.SGD","IE00B3T34201.USD","LU1839511570.USD","LU1035773651.USD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU0985320562.USD","LU0965509010.AUD","LU0289739699.SGD","LU2236285917.USD","MRNA","LU1929549753.HKD","BK4548","LU0122379950.USD","LU1057294990.SGD","LU0265550946.USD","03165","LU0432979614.USD","LU1983299246.USD","LU2468319806.SGD","LU0942090050.USD","IE00B1BXHZ80.USD","LU0980610538.SGD","BK4550","LU1674673428.USD","LU2237443382.USD","SG9999001440.SGD","SG9999014575.USD","LU0238689110.USD","LU1162221912.USD","IE00B19Z3581.USD","LU2361045086.USD","LU0882574055.USD","LU2125154778.USD","LU0053666078.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","LU2360032135.SGD","LU2417539215.USD","SG9999014559.SGD","LU0320765489.SGD","LU0203345920.USD","LU2362540622.SGD","LU1941712348.USD","LU0823434583.USD","IE00BSNM7G36.USD","LU0234572021.USD","LU0965508806.USD","LU2125909593.SGD","LU0203347892.USD","IE00BBT3K403.USD","LU1674673691.USD","LU2125154935.USD","IE0009355771.USD","LU2462157665.USD","LU0823434740.USD","SG9999002232.USD","SG9999015341.SGD","LU2237443465.HKD","LU2491050154.USD","LU2362541513.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640596407","title":"阿斯利康(AZN)股票6月1日收盤下跌3.17%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2640596407","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640596407?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 04:15","pubTimestamp":1780344918,"startTime":"0","endTime":"0","summary":"• Anselamimab 治疗轻链型淀粉样变性的试验未达到主要终点。\n• FDA 延长了乳腺癌疗法 camizestrant 的审查期限。\n• 积极的试验结果和分析师评级未能抵消挫折带来的影响。","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20251024/AstraZeneca-000ba9f6d3d446b080935cd9fe1dade4.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/AstraZeneca-000ba9f6d3d446b080935cd9fe1dade4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/261939880-market-movers-azn-20260601","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B3T34201.USD","AZNH","LU0109394709.USD","LU2237443622.USD","BK4007","BK4568","LU2236285917.USD","LU0058720904.USD","LU2237443895.HKD","AZN","BK4585","LU2237443978.SGD","LU2237443382.USD","LU2456880835.USD","LU1829250122.USD","LU2462157665.USD","BK4588","LU2237443465.HKD","LU2417539215.USD","LU2237443549.SGD","LU0889565916.HKD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":7,"totalSize":162,"code":"91000000","status":"200"}]}}